Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + BI 836826 in R/R CLL
NCT02538614Phase 1Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 836826 in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants Experienced Dose Limiting Toxicities at 7 weeks, Complete Response Rate at 18 months and 1 more. Started Dec 2015; status: terminated.
02
Drugs
BI 836826
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02538614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538614.